Emilio Itarte

Dr. Emilio Itarte


Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2017 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
LFLaura Ferrer Font
Laura Ferrer Font
LSLucia Villamañan de Santiago
Lucia Villamañan de Santiago
NANuria Arias-Ramos
Nuria Arias-Ramos
JVJordi Vilardell
Jordi Vilardell
MPMaria Plana
Maria Plana
Ana Paula CandiotaAna Paula Candiota
Ana Paula Candiota
Glioblastoma (GBM) causes poor survival in patients even with aggressive treatment. Temozolomide (TMZ) is the standard chemotherapeutic choice for GBM treatment but resistance always ensues. Protein kinase CK2 (CK2) contributes to tumour development and proliferation in cancer, and it is overexpressed in human GBM. Accordingly, targeting CK2 in GBM may benefit patients. Our goal has been to evaluate whether CK2 inhibitors (iCK2s) could increase survival in an immunocompetent preclinical GBM model. Cultured GL261 cells were treated with different iCK2s including CX-4945, and target effects evaluated in vitro. CX-4945 was found to decrease CK2 activity and Akt(S129) phosphorylation in GL261 cells. Longitudinal in vivo studies with CX-4945 alone or in combination with TMZ were performed in tumour-bearing mice. Increase in survival (p < 0.05) was found with combined CX-4945 and TMZ metronomic treatment (54.7 ± 11.9 days, n = 6) when compared to individual metronomic treatments (CX-4945: 24.5 ± 2.0 and TMZ: 38.7 ± 2.7, n = 6) and controls (22.5 ± 1.2, n = 6). Despite this, CX-4945 did not improve mice outcome when administered on every/alternate days, either alone or in combination with 3-cycle TMZ. The highest survival rate was obtained with the metronomic combined TMZ+CX-4945 every 6 days, pointing to the participation of the immune system or other ancillary mechanism in therapy response.

7 January 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
EAEstefania Alcaraz
Estefania Alcaraz
JVJordi Vilardell
Jordi Vilardell
CBChristian Borgo
Christian Borgo
ESEduard Sarró
Eduard Sarró
MPMaria Plana
Maria Plana
Maria RuzzeneMaria Ruzzene
Maria Ruzzene
The PI3K/Akt pathway is interconnected to protein kinase CK2, which directly phosphorylates Akt1 at S129. We have previously found that, in HK-2 renal cells, downregulation of the CK2 regulatory subunit β (shCK2β cells) reduces S129 Akt phosphorylation. Here, we investigated in more details how the different CK2 isoforms impact on Akt and other signaling pathways. We found that all CK2 isoforms phosphorylate S129 in vitro, independently of CK2β. However, in HK-2 cells the dependence on CK2β was confirmed by rescue experiments (CK2β re-expression in shCK2β HK-2 cells), suggesting the presence of additional components that drive Akt recognition by CK2 in cells. We also found that CK2β downregulation altered the phosphorylation ratio between the two canonical Akt activation sites (pT308 strongly reduced, pS473 slightly increased) in HK-2 cells. Similar results were found in other cell lines where CK2β was stably knocked out by CRISPR-Cas9 technology. The phosphorylation of rpS6 S235/S236, a downstream effector of Akt, was strongly reduced in shCK2β HK-2 cells, while the phosphorylation of two Akt direct targets, PRAS40 T246 and GSK3β S9, was increased. Differently to what observed in response to CK2β down-regulation, the chemical inhibition of CK2 activity by cell treatment with the specific inhibitor CX-4945 reduced both the Akt canonical sites, pT308 and pS473. In CX-4945-treated cells, the changes in rpS6 pS235/S236 and GSK3β pS9 mirrored those induced by CK2β knock-down (reduction and slight increase, respectively); on the contrary, the effect on PRAS40 pT246 phosphorylation was sharply different, being strongly reduced by CK2 inhibition; this suggests that this Akt target might be dependent on Akt pS473 status in HK-2 cells. Since PI3K/Akt and ERK1/2/p90rsk pathways are known to be interconnected and both modulated by CK2, with GSK3β pS9 representing a convergent point, we investigated if ERK1/2/p90rsk signaling was affected by CK2β knock-down and CX-4945 treatment in HK-2 cells. We found that p90rsk was insensitive to any kind of CK2 targeting; therefore, the observation that, similarly, GSK3β pS9 was not reduced by CK2 blockade suggests that GSK3β phosphorylation is mainly under the control of p90rsk in these cells. However, we found that the PI3K inhibitor LY294002 reduced GSK3β pS9, and concomitantly decreased Snail1 levels (a GSK3β target and Epithelial-to-Mesenchymal transition marker). The effects of LY294002 were observed also in CK2β-downregulated cells, suggesting that reducing GSK3β pS9 could be a strategy to control Snail1 levels in any situation where CK2β is defective, as possibly occurring in cancer cells.

19 December 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
JVJordi Vilardell
Jordi Vilardell
EAEstefania Alcaraz
Estefania Alcaraz
ESEduard Sarró
Eduard Sarró
ETEnric Trilla
Enric Trilla
TCThaïs Cuadros
Thaïs Cuadros
EIEmilio Itarte
Emilio Itarte
Under-expression of CK2 subunit in ccRCC represents a complementary biomarker of p-STAT3 Ser727 that correlates with patient survival Under-expression of CK2β subunit in ccRCC represents a complementary biomarker of p-STAT3 Ser727 that correlates with patient survival

1 July 1994 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
RBR. Bosser
R. Bosser
JRJoan Roig
Joan Roig
EIEmilio Itarte
Emilio Itarte
OBO. Bachs
O. Bachs

1 March 2013 in European Urology Supplements
Verified
Journal Article
Closed access
EHEnrique Trilla Herrera
Enrique Trilla Herrera
DLD. Lorente
D. Lorente
MLM.A. López-Pacios
M.A. López-Pacios
TCT. Cuadros
T. Cuadros
MVM. Vilà
M. Vilà
JMJuan Morote
Juan Morote